These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36983050)

  • 1. A Therapeutic Vaccine Targeting Rat BORIS (CTCFL) for the Treatment of Rat Breast Cancer Tumors.
    Loukinov D; Anderson AL; Mkrtichyan M; Ghochikyan A; Rivero-Hinojosa S; Tucker J; Lobanenkov V; Agadjanyan MG; Nelson EL
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CTCFL/BORIS for the immunotherapy of cancer.
    Loukinov D
    Cancer Immunol Immunother; 2018 Dec; 67(12):1955-1965. PubMed ID: 30390146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.
    Loukinov D; Ghochikyan A; Mkrtichyan M; Ichim TE; Lobanenkov VV; Cribbs DH; Agadjanyan MG
    J Cell Biochem; 2006 Aug; 98(5):1037-43. PubMed ID: 16741971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.
    Ghochikyan A; Mkrtichyan M; Loukinov D; Mamikonyan G; Pack SD; Movsesyan N; Ichim TE; Cribbs DH; Lobanenkov VV; Agadjanyan MG
    J Immunol; 2007 Jan; 178(1):566-73. PubMed ID: 17182597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
    Alberti L; Losi L; Leyvraz S; Benhattar J
    PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.
    Mkrtichyan M; Ghochikyan A; Davtyan H; Movsesyan N; Loukinov D; Lobanenkov V; Cribbs DH; Laust AK; Nelson EL; Agadjanyan MG
    Cell Immunol; 2011; 270(2):188-97. PubMed ID: 21641588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
    Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
    Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
    Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
    Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice.
    Mkrtichyan M; Ghochikyan A; Loukinov D; Davtyan H; Ichim TE; Cribbs DH; Lobanenkov VV; Agadjanyan MG
    Gene Ther; 2008 Jan; 15(1):61-4. PubMed ID: 17972923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
    Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
    Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
    Horibe R; Hirohashi Y; Asano T; Mariya T; Suzuki T; Takaya A; Saijo H; Shionoya Y; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Watanabe K; Atsuyama E; Toji S; Hirano H; Hasegawa T; Takahashi H; Sato N; Torigoe T
    PLoS One; 2017; 12(3):e0171460. PubMed ID: 28248963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and evaluation of cell and animal models expressing BORIS subfamily 2 variant.
    Qin L; Liu ZJ; Xian LJ; Hu L; Fu Q; Chen LH; Qin Y
    Ann Transl Med; 2022 Jun; 10(11):632. PubMed ID: 35813346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VRP immunotherapy targeting neu: treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model.
    Laust AK; Sur BW; Wang K; Hubby B; Smith JF; Nelson EL
    Breast Cancer Res Treat; 2007 Dec; 106(3):371-82. PubMed ID: 17351745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoprotective effect of an in silico designed multiepitope cancer vaccine with BORIS cancer-testis antigen target in a murine mammary carcinoma model.
    Mahdevar E; Kefayat A; Safavi A; Behnia A; Hejazi SH; Javid A; Ghahremani F
    Sci Rep; 2021 Nov; 11(1):23121. PubMed ID: 34848739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BORIS/CTCFL expression activates the TGFβ signaling cascade and induces Drp1 mediated mitochondrial fission in neuroblastoma.
    Makani VKK; Mendonza JJ; Edathara PM; Yerramsetty S; Pal Bhadra M
    Free Radic Biol Med; 2021 Nov; 176():62-72. PubMed ID: 34534628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
    Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
    Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BORIS in human cancers -- a review.
    Martin-Kleiner I
    Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of BORIS/CTCFL leads to ROS-dependent cellular senescence and drug sensitivity in MYCN-amplified neuroblastoma.
    Rao GK; Makani VKK; Mendonza JJ; Edathara PM; Patel N; Ramakrishna M; Cilamkoti P; Chiring Phukon J; Jose J; Bhadra U; Bhadra MP
    FEBS J; 2022 May; 289(10):2915-2934. PubMed ID: 34854238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the epigenetic factor BORIS (CTCFL) in the human genome.
    de Necochea-Campion R; Ghochikyan A; Josephs SF; Zacharias S; Woods E; Karimi-Busheri F; Alexandrescu DT; Chen CS; Agadjanyan MG; Carrier E
    J Transl Med; 2011 Dec; 9():213. PubMed ID: 22168535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of hTERT and stemness genes in BORIS/CTCFL positive cells isolated from embryonic cancer cells.
    Alberti L; Renaud S; Losi L; Leyvraz S; Benhattar J
    PLoS One; 2014; 9(10):e109921. PubMed ID: 25279549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.